The steepest increases in valuation often occur early in a biopharmaceutical company's life. However, growing a new biopharmaceutical company can be extraordinarily difficult and involves orchestrating many different disciplines: strong technology, a protected proprietary position, experienced management, well regarded scientific or medical advisors, a sensible company structure, a cohesive business strategy, a strong Board of Directors, and external validation of the technology and/or business model.

While obtaining early stage capital is critical, more significant challenges involve building a management team and rapidly developing a technology or product. Seaflower Ventures was formed with these challenges in mind. We also believe that effective early stage life science investing also requires a tolerance for risk and uncertainty, the ability to calmly work through inevitable problems, and the courage to break away from conventional thinking.

Seaflower focuses exclusively on early stage investing, helping scientists, clinicians, technologists and entrepreneurs who are passionate about solving unmet medical and market needs work through the many challenges involved in building a business. Through a unique combination of focus, resources, and experience, Seaflower Ventures helps entrepreneurs build thriving life science and medical technology companies.